[HTML][HTML] Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections
DRA Sanya, D Onésime, G Vizzarro, N Jacquier - BMC microbiology, 2023 - Springer
The opportunistic human pathogen Pseudomonas aeruginosa is the causal agent of a wide
variety of infections. This non-fermentative Gram-negative bacillus can colonize zones …
variety of infections. This non-fermentative Gram-negative bacillus can colonize zones …
New Ni (II) and Pd (II) complexes bearing derived sulfa drug ligands: synthesis, characterization, DFT calculations, and in silico and in vitro biological activity studies
MA Bourouai, K Si Larbi, A Bouchoucha… - Biometals, 2023 - Springer
In the present study, the synthesis of six new Ni (II) and Pd (II) complexes with three derived
sulfamethoxazole drug ligands is reported. The coordination mode, geometry, and chemical …
sulfamethoxazole drug ligands is reported. The coordination mode, geometry, and chemical …
Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability …
Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
[HTML][HTML] Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa …
I Lopez-Montesinos, MM Montero, S Domene-Ochoa… - Antibiotics, 2022 - mdpi.com
This study correlates in vivo findings in a patient with an extensively drug-resistant (XDR) P.
aeruginosa infection who developed resistance to ceftazidime-avibactam (CAZ-AVI) with in …
aeruginosa infection who developed resistance to ceftazidime-avibactam (CAZ-AVI) with in …
[HTML][HTML] Use of WATCH antibiotics prior to presentation to the hospital in rural Burkina Faso
D Valia, B Ingelbeen, B Kaboré, I Karama… - … Resistance & Infection …, 2022 - Springer
Background In low-and middle-income countries, the prevalence of antimicrobial resistance
(AMR) is increasing. To control AMR, WHO recommends monitoring antibiotic use, in …
(AMR) is increasing. To control AMR, WHO recommends monitoring antibiotic use, in …
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
MM Montero, S Domene-Ochoa… - Microbiology …, 2022 - Am Soc Microbiol
The aim of this study was to compare the efficacy of intermittent (1-h), extended (4-h), and
continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant …
continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant …